Qiagen to launch rapid portable SARS-CoV-2 antigen test

By LabPulse.com staff writers

September 10, 2020 -- Qiagen plans to launch the Access Anti-SARS-CoV-2 antigen test, a rapid portable test that can detect novel coronavirus antigens in people with active infections in less than 15 minutes.

About 30 swab samples can be processed per hour using a small digital detection system, according to the company.

A version of the test for labs and one for point-of-care use, both of which were developed in collaboration with Ellume, are expected to become available in the last quarter of 2020. The test is designed for environments that require a high volume of fast and accurate test results.

Qiagen launches 10-minute SARS-CoV-2 test
Qiagen announced the U.S. launch of a new digital SARS-CoV-2 detection test that can be done on a portable device. The device provides results in about...
Qiagen appoints new supervisory board chairman
Qiagen has appointed Lawrence Rosen as the new chairman of its supervisory board, effective immediately. The news comes in the wake of the failure of...
Thermo Fisher's acquisition of Qiagen falls short
Thermo Fisher Scientific has terminated its acquisition of Qiagen after the company was unable to secure the number of shares needed to proceed with the...
Thermo Fisher increases Qiagen acquisition offer
Thermo Fisher Scientific and Qiagen have amended their acquisition agreement with an increase from the original offer price of 39 euros ($44.61 U.S.)...
Qiagen launches therascreen BRAF test
Qiagen is launching a therascreen BRAF test as a companion diagnostic to Pfizer's targeted drug Braftovi in metastatic colorectal cancer.

Copyright © 2020 LabPulse.com

Last Updated ls 9/21/2020 8:43:44 AM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current